危重症患者纤溶抵抗的床旁诊断与监测:一项可行性研究结果
这项前瞻性观察性研究对105例危重症患者行全血ClotPro黏弹性检测,58例被判定为纤溶抵抗(TPA-test血凝块溶解时间>300 s),其中32例接受追加t-PA和/或纤溶酶原的连续体外实验以观察溶解时间变化。体外实验出现不同反应组,补充t-PA仅或补充纤溶酶原加t-PA后纤溶增加,基线TPA-test溶解时间>1000 s与后者相关。在一例急性呼吸衰竭合并纤溶抵抗患者的干预研究中,24小时静脉低剂量阿替普酶输注期间系列TPA-test溶解时间逐步下降25%。作者认为该检测可用于探究纤溶抵抗机制、指导纠正治疗并实时监测疗效。
要点
- 105例危重症患者行全血ClotPro黏弹性检测,58例TPA-test血凝块溶解时间>300 s判定为纤溶抵抗。
- 32例纤溶抵抗患者行体外补充实验:补充t-PA仅或补充纤溶酶原加t-PA后纤溶增加,出现不同反应组。
- 基线TPA-test溶解时间>1000 s与需要补充纤溶酶原加t-PA的反应组相关。
- 一例急性呼吸衰竭合并纤溶抵抗患者,24小时静脉低剂量阿替普酶输注期间系列TPA-test溶解时间逐步下降25%。
- 作者认为ClotPro黏弹性检测及实验性检测可用于探究纤溶抵抗机制、指导纠正治疗并实时监测疗效。
适用人群与场景
- 危重症患者,包括脓毒症、急性呼吸衰竭(ARF)和创伤等纤溶反应降低、可能发生广泛血栓和多器官衰竭的危重状态。
- 前瞻性观察性研究纳入105例危重症患者;干预研究为1例急性呼吸衰竭合并纤溶抵抗患者。
- 纳入纤溶抵抗判定标准为TPA-test血凝块溶解时间>300 s的58例患者,其中32例接受连续体外实验。
诊断标准与关键阈值
- 纤溶抵抗判定:TPA-test(组织因子激活凝血并加t-PA加速纤溶)血凝块溶解时间>300 s。
- 基线TPA-test溶解时间>1000 s与体外补充纤溶酶原加t-PA后纤溶增加的反应组相关。
处置流程与药物剂量
- 对危重症患者行全血ClotPro黏弹性检测,TPA-test血凝块溶解时间>300 s判定为纤溶抵抗。
- 对纤溶抵抗患者可行连续体外实验:TPA-test中追加t-PA和/或纤溶酶原,观察溶解时间变化以区分反应组。
- 一例急性呼吸衰竭合并纤溶抵抗患者接受24小时静脉低剂量阿替普酶输注,并用标准ClotPro黏弹性检测前瞻性监测凝血和纤溶。
研究设计与关键结果
- 前瞻性观察性研究纳入105例危重症患者行全血ClotPro黏弹性检测,58例判定为纤溶抵抗(TPA-test血凝块溶解时间>300 s)。
- 58例纤溶抵抗患者中32例接受连续体外全血黏弹性检测,重复TPA-test追加t-PA和/或纤溶酶原并测定对溶解时间的影响。
- 体外实验出现不同反应组:补充t-PA仅或补充纤溶酶原加t-PA后纤溶增加;基线TPA-test溶解时间>1000 s与后者相关。
- 一例急性呼吸衰竭合并纤溶抵抗患者的干预研究中,24小时静脉低剂量阿替普酶输注期间系列TPA-test溶解时间逐步下降25%。
证据类型、等级与局限
- 证据类型:前瞻性观察性研究(可行性研究)及1例干预研究。
- 作者结论:ClotPro黏弹性检测、相关TPA-test及新型实验性检测可用于探究纤溶抵抗机制、指导纠正治疗并实时监测疗效。
- 作者认为这种精准医学和个体化治疗策略有潜力提高治疗获益并减少危重症患者不良事件。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为ClotPro黏弹性检测及TPA-test可用于识别危重症患者的纤溶抵抗,并指导纠正治疗和实时监测疗效。
- 作者认为基于该检测的精准医学和个体化治疗策略有潜力提高治疗获益并减少不良事件。
- 原文未据此给出推荐。
指南或共识出处
- VETtiPAT-ARF临床试验(ClinicalTrials.gov NCT05540834,2022年9月15日回顾性注册)正在评估ClotPro指导的t-PA(阿替普酶)给药在合并纤溶抵抗的急性呼吸衰竭患者中的应用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Fibrinolysisis is essential for vascular blood flow maintenance and is triggered by endothelial and platelet release of tissue plasminogen activator (t-PA). In certain critical conditions, e.g. sepsis, acute respiratory failure (ARF) and trauma, the fibrinolytic response is reduced and may lead to widespread thrombosis and multi-organ failure. The mechanisms underpinning fibrinolysis resistance include reduced t-PA expression and/or release, reduced t-PA and/or plasmin effect due to elevated inhibitor levels, increased consumption and/or clearance. This study in critically ill patients with fibrinolysis resistance aimed to evaluate the ability of t-PA and plasminogen supplementation to restore fibrinolysis with assessment using point-of-care ClotPro viscoelastic testing (VET).
METHODS: In prospective, observational studies, whole-blood ClotPro VET evaluation was carried out in 105 critically ill patients. In 32 of 58 patients identified as fibrinolysis-resistant (clot lysis time > 300 s on the TPA-test: tissue factor activated coagulation with t-PA accelerated fibrinolysis), consecutive experimental whole-blood VET was carried out with repeat TPA-tests spiked with additional t-PA and/or plasminogen and the effect on lysis time determined. In an interventional study in a patient with ARF and fibrinolysis resistance, the impact of a 24 h intravenous low-dose alteplase infusion on coagulation and fibrinolysis was prospectively monitored using standard ClotPro VET.
RESULTS: Distinct response groups emerged in the ex vivo experimental VET, with increased fibrinolysis observed following supplementation with (i) t-PA only or (ii) plasminogen and t-PA. A baseline TPA-test lysis time of > 1000 s was associated with the latter group. In the interventional study, a gradual reduction (25%) in serial TPA-test lysis times was observed during the 24 h low-dose alteplase infusion.
CONCLUSIONS: ClotPro viscoelastic testing, the associated TPA-test and the novel experimental assays may be utilised to (i) investigate the potential mechanisms of fibrinolysis resistance, (ii) guide corrective treatment and (iii) monitor in real-time the treatment effect. Such a precision medicine and personalised treatment approach to the management of fibrinolysis resistance has the potential to increase treatment benefit, while minimising adverse events in critically ill patients.
TRIAL REGISTRATION: VETtiPAT-ARF, a clinical trial evaluating ClotPro-guided t-PA (alteplase) administration in fibrinolysis-resistant patients with ARF, is ongoing (ClinicalTrials.gov NCT05540834 ; retrospectively registered September 15th 2022).
参考来源
- Coupland LA, Rabbolini DJ, Schoenecker JG, et al. Point-of-care diagnosis and monitoring of fibrinolysis resistance in the critically ill: results from a feasibility study. Crit Care. 2023. PMID: 36765421. doi:10.1186/s13054-023-04329-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。